MedTrace Logo

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

NCT02580474 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-07-18

No results posted yet for this study

Summary

Safety and Efficacy of DAAs (Daclatasvir+Asunaprevir) in patients with chronic hepatitis C and chronic renal failure will be assessed.

Conditions

  • Hepatitis C

Interventions

DRUG

Daclatasvir plus Asunaprevir

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Soonchunhyang University Hospital

    collaborator OTHER

  • Dankook University

    collaborator OTHER

  • Chungnam National University Hospital

    collaborator OTHER

  • Konyang University Hospital

    collaborator OTHER

  • Eulji University Hospital

    collaborator OTHER

  • Saint Vincent's Hospital, Korea

    collaborator OTHER

  • Konkuk University Hospital

    collaborator OTHER

  • Cheongju St. Mary's Hospital, Cheongju, Korea

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • Korea University Guro Hospital

    collaborator OTHER

  • Eulji General Hospital

    collaborator OTHER

  • Myeong Jun Song

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02580474 on ClinicalTrials.gov